Caffeine and uric acid mediate glutathione synthesis for neuroprotection

Neuroscience

Volumn 181, Issue , 2011, Pages 206-215

  Aoyama, K ^a   Matsumura, N ^a   Watabe, M ^a   Wang, F ^a   Kikuchi Utsumi, K ^a   Nakaki, T ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Caffeine; Cysteine uptake; EAAC1; Glutathione; Neuroprotection; Uric acid

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ALLOPURINOL; CAFFEINE; CARRIER PROTEIN; CYSTEINE; GLUTATHIONE; HIPPOCAMPAL EXCITATORY AMINO ACID CARRIER 1; ROLIPRAM; UNCLASSIFIED DRUG; URIC ACID;

AMINO ACID TRANSPORT; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GLUTATHIONE METABOLISM; HIPPOCAMPAL CA1 REGION; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATION; PRIORITY JOURNAL;

ANIMALS; CAFFEINE; CELL LINE, TUMOR; GLUTATHIONE; HUMANS; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; ORGAN CULTURE TECHNIQUES; OXIDATIVE STRESS; URIC ACID;

EID: 79953701008     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.02.047     Document Type: Article

References (47)

1. Allameh A., Maleklou N., Zargari M., Sanati M.H. The influence of uric acid treatments on liver glutathione system prevent oxidative damages in experimental autoimmune encephalomyelitis mice. Neurosci Lett 2008, 439:111-115.
2. Alvira D., Yeste-Velasco M., Folch J., Casadesus G., Smith M.A., Pallas M., Camins A. Neuroprotective effects of caffeine against complex I inhibition-induced apoptosis are mediated by inhibition of the Atm/p53/E2F-1 path in cerebellar granule neurons. J Neurosci Res 2007, 85:3079-3088.
3. Ames B.N., Cathcart R., Schwiers E., Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981, 78:6858-6862.
4. Aoyama K., Matsumura N., Watabe M., Nakaki T. Oxidative stress on EAAC1 is involved in MPTP-induced glutathione depletion and motor dysfunction. Eur J Neurosci 2008, 27:20-30.
5. Aoyama K., Suh S.W., Hamby A.M., Liu J., Chan W.Y., Chen Y., Swanson R.A. Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse. Nat Neurosci 2006, 9:119-126.
6. Arendash G.W., Schleif W., Rezai-Zadeh K., Jackson E.K., Zacharia L.C., Cracchiolo J.R., Shippy D., Tan J. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience 2006, 142:941-952.
7. Aronowski J., Strong R., Shirzadi A., Grotta J.C. Ethanol plus caffeine (caffeinol) for treatment of ischemic stroke: preclinical experience. Stroke 2003, 34:1246-1251.
8. Ascherio A., Zhang S.M., Hernan M.A., Kawachi I., Colditz G.A., Speizer F.E., Willett W.C. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001, 50:56-63.
9. Barhoumi R., Bowen J.A., Stein L.S., Echols J., Burghardt R.C. Concurrent analysis of intracellular glutathione content and gap junctional intercellular communication. Cytometry 1993, 14:747-756.
10. Bateup H.S., Svenningsson P., Kuroiwa M., Gong S., Nishi A., Heintz N., Greengard P. Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci 2008, 11:932-939.
11. Canas P.M., Porciuncula L.O., Cunha G.M., Silva C.G., Machado N.J., Oliveira J.M., Oliveira C.R., Cunha R.A. Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. J Neurosci 2009, 29:14741-14751.
12. Chen G.Q., Chen Y.Y., Wang X.S., Wu S.Z., Yang H.M., Xu H.Q., He J.C., Wang X.T., Chen J.F., Zheng R.Y. Chronic caffeine treatment attenuates experimental autoimmune encephalomyelitis induced by guinea pig spinal cord homogenates in Wistar rats. Brain Res 2010, 1309:116-125.
13. Chen J.F., Xu K., Petzer J.P., Staal R., Xu Y.H., Beilstein M., Sonsalla P.K., Castagnoli K., Castagnoli N., Schwarzschild M.A. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001, 21:RC143.
14. Cunha R.A., Johansson B., van der Ploeg I., Sebastiao A.M., Ribeiro J.A., Fredholm B.B. Evidence for functionally important adenosine A2a receptors in the rat hippocampus. Brain Res 1994, 649:208-216.
15. Dall'Igna O.P., Fett P., Gomes M.W., Souza D.O., Cunha R.A., Lara D.R. Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. Exp Neurol 2007, 203:241-245.
16. Dall'Igna O.P., Porciuncula L.O., Souza D.O., Cunha R.A., Lara D.R. Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity. Br J Pharmacol 2003, 138:1207-1209.
17. Dringen R. Metabolism and functions of glutathione in brain. Prog Neurobiol 2000, 62:649-671.
18. Dringen R., Pfeiffer B., Hamprecht B. Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. J Neurosci 1999, 19:562-569.
19. Du Y., Chen C.P., Tseng C.Y., Eisenberg Y., Firestein B.L. Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity. Glia 2007, 55:463-472.
20. Elion G.B., Kovensky A., Hitchings G.H. Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem Pharmacol 1966, 15:863-880.
21. Fredholm B.B., Battig K., Holmen J., Nehlig A., Zvartau E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999, 51:83-133.
22. Gong B., Vitolo O.V., Trinchese F., Liu S., Shelanski M., Arancio O. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest 2004, 114:1624-1634.
23. Hensley K., Maidt M.L., Yu Z., Sang H., Markesbery W.R., Floyd R.A. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci 1998, 18:8126-8132.
24. Jenner P. Oxidative damage in neurodegenerative disease. Lancet 1994, 344:796-798.
25. Jin S.L., Richard F.J., Kuo W.P., D'Ercole A.J., Conti M. Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice. Proc Natl Acad Sci U S A 1999, 96:11998-12003.
26. Kaplan G.B., Greenblatt D.J., Leduc B.W., Thompson M.L., Shader R.I. Relationship of plasma and brain concentrations of caffeine and metabolites to benzodiazepine receptor binding and locomotor activity. J Pharmacol Exp Ther 1989, 248:1078-1083.
27. Kehr W., Debus G., Neumeister R. Effects of rolipram, a novel antidepressant, on monoamine metabolism in rat brain. J Neural Transm 1985, 63:1-12.
28. Kutzing M.K., Firestein B.L. Altered uric acid levels and disease states. J Pharmacol Exp Ther 2008, 324:1-7.
29. Li X., Valencia A., Sapp E., Masso N., Alexander J., Reeves P., Kegel K.B., Aronin N., Difiglia M. Aberrant Rab11-dependent trafficking of the neuronal glutamate transporter EAAC1 causes oxidative stress and cell death in Huntington's disease. J Neurosci 2010, 30:4552-4561.
30. Lindsay J., Laurin D., Verreault R., Hebert R., Helliwell B., Hill G.B., McDowell I. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 2002, 156:445-453.
31. Maia L., de Mendonca A. Does caffeine intake protect from Alzheimer's disease?. Eur J Neurol 2002, 9:377-382.
32. Nakaso K., Ito S., Nakashima K. Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells. Neurosci Lett 2008, 432:146-150.
33. Nehlig A., Daval J.L., Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Brain Res Rev 1992, 17:139-170.
34. Nishida Y. Inhibition of lipid peroxidation by methylated analogues of uric acid. J Pharm Pharmacol 1991, 43:885-887.
35. Pan J., Zhang Q., Zhang Y., Ouyang Z., Zheng Q., Zheng R. Oxidative stress in heroin administered mice and natural antioxidants protection. Life Sci 2005, 77:183-193.
36. Ramassamy C., Averill D., Beffert U., Theroux L., Lussier-Cacan S., Cohn J.S., Christen Y., Schoofs A., Davignon J., Poirier J. Oxidative insults are associated with apolipoprotein E genotype in Alzheimer's disease brain. Neurobiol Dis 2000, 7:23-37.
37. -, in the mouse brain. J Neurosci 2002, 22:8028-8033.
38. Scott G.S., Cuzzocrea S., Genovese T., Koprowski H., Hooper D.C. Uric acid protects against secondary damage after spinal cord injury. Proc Natl Acad Sci U S A 2005, 102:3483-3488.
39. Shanker G., Allen J.W., Mutkus L.A., Aschner M. The uptake of cysteine in cultured primary astrocytes and neurons. Brain Res 2001, 902:156-163.
40. Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., Javoy-Agid F., Jenner P., Marsden C.D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994, 36:348-355.
41. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 1969, 27:502-522.
42. Tran M.H., Yamada K., Nakajima A., Mizuno M., He J., Kamei H., Nabeshima T. Tyrosine nitration of a synaptic protein synaptophysin contributes to amyloid beta-peptide-induced cholinergic dysfunction. Mol Psychiatry 2003, 8:407-412.
43. Watabe M., Aoyama K., Nakaki T. A dominant role of GTRAP3-18 in neuronal glutathione synthesis. J Neurosci 2008, 28:9404-9413.
44. Xu K., Xu Y., Brown-Jermyn D., Chen J.F., Ascherio A., Dluzen D.E., Schwarzschild M.A. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci 2006, 26:535-541.
45. Xu K., Xu Y.H., Chen J.F., Schwarzschild M.A. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neurosci Lett 2002, 322:13-16.
46. Yang L., Calingasan N.Y., Lorenzo B.J., Beal M.F. Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV. Exp Neurol 2008, 211:311-314.
47. Zerangue N., Kavanaugh M.P. Interaction of l-cysteine with a human excitatory amino acid transporter. J Physiol 1996, 493(Pt 2):419-423.